Business Wire

  1. Altasciences And Evidence Matters Advance AI-Driven Drug Development With Nonclinical Automation Breakthrough 7/7/2026

    Altasciences, a fully integrated early-phase drug development organization, and Evidence Matters, a pioneer in clinical trial data science, are pleased to announce a successful proof-of-concept (POC) of RegulatoryFlow (“RegFlow”), following the announcement of the companies’ strategic collaboration in August 2025.

  2. INTENT Biologics Receives FDA Breakthrough Therapy Designation For PEP Biologic For Its Phase 3 Ready Flagship Indication 7/1/2026

    INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for PEP Biologic for the treatment of diabetic foot ulcers (DFU) under IND 019567.

  3. Altasciences Supports Key Development Milestone For Steel Therapeutics' Lead Therapeutic Candidate, Fizurex 6/30/2026

    Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex, for the treatment of anal fissures.

  4. Enhertu Approved In The EU As First Tumor Agnostic HER2 Directed Therapy And Antibody Drug Conjugate For Patients With Previously Treated HER2 Positive Metastatic Solid Tumors 6/29/2026

    Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options.

  5. BioStrand, ImmunoPrecise Antibodies' Subsidiary, Announces Immediate Commercial Offering Of Groundbreaking Software With Customizable Interface For AI-Driven Drug Discovery 6/10/2024

    ImmunoPrecise Antibodies Ltd. (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, today announces the commercial release of LENSai API, hereafter referred to as the ‘software’, by its subsidiary, BioStrand. This advanced AI-driven software solution is available immediately.

  6. Every Cure Deploys BioPhy's Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases 4/30/2024

    BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

  7. X-Chem Acquires Glamorous AI — Immediately Creating A Leader In DEL-Powered AI Solutions 10/28/2021

    X-Chem, the pioneer of DNA-encoded library (DEL) technology and a recognized leader in generating actionable results to drive small molecule drug discovery, today announced the acquisition of Glamorous AI, a leader in artificial intelligence (AI) solutions for drug discovery.

  8. Pfizer Establishes Precision Medicine Research Collaboration With Medco 11/1/2011
    Pfizer Inc. (NYSE: PFE) announced recently that it has established a research collaboration with Medco Health Solutions, Inc. and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes
  9. Spectrum Pharmaceuticals To Present At The Rodman & Renshaw 10th Annual Global Healthcare Investment Conference 11/5/2008
    Spectrum Pharmaceuticals, Inc., announced today that an overview of the Company’s business strategy will be presented at the Rodman & Renshaw Annual 10th Annual Global Healthcare Investment Conference, on Tuesday, November 11, 2008, at 12:00 p.m. Eastern
  10. AgilityBio And Advinus Announce Partnership To Introduce Digital Pathology Services In Pre Clinical Research 11/5/2008
    AgilityBio, a division of BioImagene Inc, and Advinus Therapeutics, a TATA enterprise, announced a partnership that will enable providing imaging services in conjunction with preclinical development services offered by Advinus